Shockwave Medical, Inc. (NASDAQ:SWAV) Stock Position Lowered by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. lowered its position in shares of Shockwave Medical, Inc. (NASDAQ:SWAV) by 10.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,775 shares of the company’s stock after selling 200 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Shockwave Medical were worth $338,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of SWAV. Lindbrook Capital LLC lifted its position in shares of Shockwave Medical by 64.8% during the 3rd quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock valued at $30,000 after acquiring an additional 59 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Shockwave Medical by 297.4% during the third quarter. EverSource Wealth Advisors LLC now owns 155 shares of the company’s stock worth $31,000 after purchasing an additional 116 shares during the period. Asset Management One Co. Ltd. purchased a new stake in shares of Shockwave Medical during the fourth quarter valued at $34,000. Operose Advisors LLC acquired a new position in shares of Shockwave Medical in the 3rd quarter valued at $49,000. Finally, Venturi Wealth Management LLC purchased a new position in Shockwave Medical in the 3rd quarter worth about $82,000. 95.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SWAV has been the subject of several recent analyst reports. SVB Leerink reiterated a “market perform” rating and issued a $335.00 target price (down from $361.00) on shares of Shockwave Medical in a report on Monday, April 8th. CL King reiterated a “neutral” rating on shares of Shockwave Medical in a research report on Monday, April 8th. Canaccord Genuity Group restated a “hold” rating and issued a $335.00 target price (up previously from $263.00) on shares of Shockwave Medical in a report on Friday, April 5th. Needham & Company LLC reiterated a “hold” rating on shares of Shockwave Medical in a report on Friday, April 5th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $335.00 price objective (up from $285.00) on shares of Shockwave Medical in a research note on Monday, April 8th. Ten investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $309.11.

Shockwave Medical Stock Performance

Shares of NASDAQ SWAV opened at $330.49 on Wednesday. The company has a debt-to-equity ratio of 1.09, a current ratio of 11.76 and a quick ratio of 10.73. Shockwave Medical, Inc. has a one year low of $157.00 and a one year high of $331.58. The business’s 50-day moving average price is $304.38 and its two-hundred day moving average price is $240.04. The company has a market capitalization of $12.40 billion, a P/E ratio of 85.40, a price-to-earnings-growth ratio of 2.46 and a beta of 0.88.

Shockwave Medical (NASDAQ:SWAV) last announced its quarterly earnings results on Monday, May 6th. The company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.45. Shockwave Medical had a return on equity of 23.97% and a net margin of 20.17%. The business had revenue of $218.80 million during the quarter, compared to analyst estimates of $207.69 million. During the same period in the previous year, the company earned $1.03 EPS. The firm’s revenue was up 35.8% on a year-over-year basis. Analysts anticipate that Shockwave Medical, Inc. will post 4.94 earnings per share for the current fiscal year.

Insider Buying and Selling at Shockwave Medical

In other news, insider Isaac Zacharias sold 4,000 shares of the stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $287.67, for a total transaction of $1,150,680.00. Following the transaction, the insider now owns 56,818 shares in the company, valued at approximately $16,344,834.06. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Shockwave Medical news, Director Laura Francis sold 1,500 shares of the business’s stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $300.00, for a total value of $450,000.00. Following the completion of the sale, the director now owns 3,551 shares of the company’s stock, valued at $1,065,300. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Isaac Zacharias sold 4,000 shares of the stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $287.67, for a total value of $1,150,680.00. Following the transaction, the insider now directly owns 56,818 shares in the company, valued at approximately $16,344,834.06. The disclosure for this sale can be found here. Insiders sold 83,120 shares of company stock worth $21,319,021 over the last ninety days. 3.40% of the stock is currently owned by insiders.

Shockwave Medical Company Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.